Analysis of lung cancer patients enrolled in CTEP (Cancer Therapy Evaluation Program)-sponsored phase i trials

Clinical Lung Cancer

Volumn 12, Issue 4, 2011, Pages 218-223

  Gadgeel, Shirish ^a   Ivy, Percy ^b   Chen, Wei ^a   Mauer, Joan ^b   Smith, Daryn ^a   Lorusso, Patricia ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical Trials; CTEP; Non small cell; Phase I; Small cell

Indexed keywords

BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MORTALITY; PHASE 1 CLINICAL TRIAL (TOPIC); RESEARCH SUBJECT; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79960381390     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.022     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev Anticancer Ther 2009; 9:1365-78.
3. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-31.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci-zumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pem-etrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97. (Pubitemid 41079796)
6. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32. (Pubitemid 41058344)
7. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-67. (Pubitemid 29075255)
8. Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010; 5:29-33.
9. Cox K, Avis M. Ethical and practical problems of early anti-cancer drug trials: a review of the literature. Eur J Cancer Care (Engl) 1996; 5:90-5. (Pubitemid 126672946)
10. Horng S, Emanuel EJ, Wilfond B, et al. Descriptions of benefits and risks in consent forms for phase i oncology trials. N Engl J Med 2002; 347:2134-40. (Pubitemid 36015126)
11. Travis K. For phase I studies, ethical and practical concerns abound. J Natl Cancer Inst 2004; 96:1354-5. (Pubitemid 39406166)
12. Tomamichel M, Jaime H, Degrate A, et al. Proposing phase I studies: patients', relatives', nurses' and specialists' perceptions. Ann Oncol 2000; 11:289-94.
13. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995; 13:1062-72.
14. Moore S. A need to try everything: patient participation in phase I trials. J Adv Nurs 2001; 33:738-47. (Pubitemid 33603217)
15. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352:895-904. (Pubitemid 40300298)
16. Roberts TG Jr, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292: 2130-40. (Pubitemid 39435104)
17. Seidenfeld J, Horstmann E, Emanuel EJ, et al. Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med 2008; 168:16-20.
18. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-7. (Pubitemid 30035956)
19. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25:2086-92. (Pubitemid 46972795)
20. Italiano A, Massard C, Bahleda R, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 2008; 19:787-92. (Pubitemid 351467383)
21. Bachelot T, Ray-Coquard I, Catimel G, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000; 11:151-6. (Pubitemid 30148727)
22. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-18.
23. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39:55-61. (Pubitemid 36020295)
24. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24:5441-7. (Pubitemid 46623178)